BioCardia to Present at BIO-Europe Spring 2024 Conference

TL;DR

**BioCardia is presenting at a big biotech conference in March, hoping to drum up interest.**

AI Summary

BioCardia, Inc. filed an 8-K on February 8, 2024, to disclose that it will be presenting at the BIO-Europe Spring 2024 conference in Barcelona, Spain, from March 18-20, 2024. This matters to investors because such presentations can increase visibility and potentially attract new investors or partnerships, which could positively impact the stock price, especially for a company in the biological products sector like BioCardia.

Why It Matters

Increased visibility at a major industry conference could lead to new partnerships or investor interest, potentially boosting BioCardia's stock value. It signals active engagement in the biotech community.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of a company presentation, which carries minimal direct financial risk.

Analyst Insight

A smart investor would monitor BioCardia's presentation at BIO-Europe Spring 2024 for any significant announcements or partnerships that could impact future performance.

Key Players & Entities

• BioCardia, Inc. (company) — the registrant filing the 8-K
• BIO-Europe Spring 2024 (event) — the conference where BioCardia will present
• Barcelona, Spain (location) — the venue for the BIO-Europe Spring 2024 conference
• March 18-20, 2024 (date) — the dates of the BIO-Europe Spring 2024 conference

Forward-Looking Statements

• BioCardia's stock price may experience a slight increase around the conference dates due to increased investor awareness. (BioCardia, Inc.) — medium confidence, target: March 18-20, 2024

FAQ

Key Financial Figures

• $0.001 B — ch registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Warrant

Filing Documents

• bcda20240207_8k.htm (8-K) — 27KB
• ex_623873.htm (EX-99.1) — 12KB
• 0001437749-24-003422.txt ( ) — 188KB
• bcda-20240208.xsd (EX-101.SCH) — 4KB
• bcda-20240208_def.xml (EX-101.DEF) — 13KB
• bcda-20240208_lab.xml (EX-101.LAB) — 17KB
• bcda-20240208_pre.xml (EX-101.PRE) — 13KB
• bcda20240207_8k_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On February 8, 2024, BioCardia, Inc. (the "Company") issued a press release announcing activation of CardiAMP HF II, a randomized controlled pivotal trial of its CardiAMP autologous cell therapy for patients with ischemic heart failure. The study was approved by the FDA in the fourth quarter of 2023 for the treatment of ischemic etiology heart failure of reduced ejection fraction. The information furnished pursuant to this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 104 BioCardia, Inc. press release dated February 8, 2024 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: February 8, 2024

View Full Filing

View this 8-K filing on SEC EDGAR